FDA-cleared profile

Limbus Contour

Limbus AI Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Limbus Contour assists trained radiation oncologists, dosimetrists, and physicists by generating anatomical contours from CT and MR images for radiation-treatment planning. The initial cleared release provided CT and MR automatic contouring on Windows and macOS, used file-system DICOM import and RT Structure Set export, and excluded tumor and tumor-CTV automatic contouring.

Clinical role
Initial anatomical contour generation before treatment planning
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
The device is not intended for digital mammography and generated contours require qualified review. The initial indication explicitly excluded automatic tumor and tumor clinical-target-volume contouring.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyRadiotherapy Planning Imaging · Multi-region
  • Workflow roleInitial anatomical contour generation before treatment planning
  • Required inputDICOM CT or MR image files from supported radiotherapy workflows; the software relies on an external treatment-planning system or DICOM viewer for image display and contour modification.
  • Output and human actionDICOM RT Structure Set files containing generated anatomical contours for import, display, review, modification, and approval in a treatment-planning system or DICOM viewer.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Limbus Contour assists trained radiation oncologists, dosimetrists, and physicists by generating anatomical contours from CT and MR images for radiation-treatment planning. The initial cleared release provided CT and MR automatic contouring on Windows and macOS, used file-system DICOM import and RT Structure Set export, and excluded tumor and tumor-CTV automatic contouring.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
Initial anatomical contour generation before treatment planning
  • Exact FDA submission
  • Checked 2026-09-03
Required input
DICOM CT or MR image files from supported radiotherapy workflows; the software relies on an external treatment-planning system or DICOM viewer for image display and contour modification.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
DICOM RT Structure Set files containing generated anatomical contours for import, display, review, modification, and approval in a treatment-planning system or DICOM viewer.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Radiation-therapy departments in hospitals, clinics, and other qualified treatment-planning facilities.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained radiation oncologists, dosimetrists, and medical physicists responsible for reviewing and modifying contours before treatment-planning use.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
The device is not intended for digital mammography and generated contours require qualified review. The initial indication explicitly excluded automatic tumor and tumor clinical-target-volume contouring.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
FDA summaries describe automatic-contouring verification and release-specific structure additions; v1.8.0 also summarizes multi-study evidence and training-data governance. Independent studies report meaningful time savings but show dosimetric consequences from unedited contours and structure-dependent failures, supporting mandatory physician review and local acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA summaries describe automatic-contouring verification and release-specific structure additions; v1.8.0 also summarizes multi-study evidence and training-data governance. Independent studies report meaningful time savings but show dosimetric consequences from unedited contours and structure-dependent failures, supporting mandatory physician review and local acceptance testing.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Prostate-plus-nodes time saved

26 minutes

  • EndpointTime saved to produce clinically acceptable contours
  • Population15 prostate-plus-nodes cases
  • Tested versionLimbus Contour v1.6.0

Prostate-only time saved

13 minutes

  • EndpointTime saved to produce clinically acceptable contours
  • Population15 prostate-only cases
  • Tested versionLimbus Contour v1.6.0

Reported DSC floor

0.7 DSC

  • EndpointAll reported contours exceeded this DSC value
  • Population30-patient v1.6.0 study
  • Tested versionLimbus Contour v1.6.0

K201232 FDA performance package for Limbus Contour

  • DesignManufacturer automatic-contouring verification and release-specific structure-model validation
  • PopulationRelease-specific CT and MR anatomical structure models described in the FDA summary
  • Scopeexact submission
  • Tested versionInitial Limbus Contour release cleared in K201232
  • IndependenceSponsor or vendor study

K201232

Manufacturer evidence submitted for substantial equivalence. The initial cleared release provided CT and MR automatic contouring on Windows and macOS, used file-system DICOM import and RT Structure Set export, and excluded tumor and tumor-CTV automatic contouring.

Clinical evaluation of Limbus for prostate and nodal radiotherapy contouring

  • DesignIndependent clinical timing, geometric, and dosimetric evaluation by three clinical oncologists
  • Population30 prostate radiotherapy patients, half with prostate-only and half with prostate-plus-nodes planning
  • Scopeproduct family
  • Tested versionLimbus Contour v1.6.0
  • Samplen=30
  • Sites1
  • IndependenceIndependent study

PMID 38627245 · PMCID PMC11135797

Five of 20 plans optimized using unedited AI structures unnecessarily compromised target coverage, reinforcing expert review.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K201232 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists. Maintain ongoing FDA and vendor surveillance.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS Radiation Oncology Model material. Evaluate the product within the radiation-therapy planning service line using net staff time after review, plan quality, rework, throughput, implementation cost, and recurring cost.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT or MR image files from supported radiotherapy workflows; the software relies on an external treatment-planning system or DICOM viewer for image display and contour modification.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · K201232 FDA decision source

  2. Routing

    Source context, not route validation: File-system import of DICOM images and export of DICOM RT Structure Sets to treatment-planning systems or DICOM viewers without a required proprietary plug-in.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · K201232 FDA decision source · Limbus Contour automatic contouring for radiation therapy

  3. AI processing

    Source context, not route validation: Local Windows or Windows Server software using CPU or optional CUDA-capable NVIDIA GPU processing. The current product-family page describes local processing without cloud transfer; macOS support applied to the initial clearance but not the later releases reviewed here.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · K201232 FDA decision source · Limbus Contour automatic contouring for radiation therapy

  4. Returned objects

    Source context, not route validation: DICOM RT Structure Set files containing generated anatomical contours for import, display, review, modification, and approval in a treatment-planning system or DICOM viewer.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · K201232 FDA decision source

  5. Viewer/worklist/report

    Unresolved route: DICOM RT Structure Set files containing generated anatomical contours for import, display, review, modification, and approval in a treatment-planning system or DICOM viewer.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · K201232 FDA decision source

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Local Windows or Windows Server software using CPU or optional CUDA-capable NVIDIA GPU processing. The current product-family page describes local processing without cloud transfer; macOS support applied to the initial clearance but not the later releases reviewed here.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
File-system import of DICOM images and export of DICOM RT Structure Sets to treatment-planning systems or DICOM viewers without a required proprietary plug-in.
  • Exact FDA submission
  • Checked 2026-09-03
Security
The current vendor page states that processing runs on local clinical computers and that patient data is not transferred to a cloud service. This reduces external data movement but does not establish the full security posture; confirm authentication, audit logs, patching, support access, backup, and incident-response controls.
  • Product family
  • Checked 2026-09-03

Request the current security package and contract controls for the proposed deployment.

Training
Only trained and qualified radiation-therapy professionals should operate the software and review, correct, and approve its outputs. Local onboarding must include release-specific limitations, failure examples, escalation, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

The initial cleared release provided CT and MR automatic contouring on Windows and macOS, used file-system DICOM import and RT Structure Set export, and excluded tumor and tumor-CTV automatic contouring. Procurement should map the installed build, modules, models, anatomies, inputs, and outputs to K201232 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that an earlier cleared release includes them.

Interoperability acceptance

File-system import of DICOM images and export of DICOM RT Structure Sets to treatment-planning systems or DICOM viewers without a required proprietary plug-in.

exact submission · checked 2026-09-03

Test representative imports, exports, identifiers, orientation, geometry, structure names, units, failure handling, and round trips in the local environment.

Clinical acceptance

Use a signed local test set spanning supported anatomies, scanners, protocols, unusual or postsurgical anatomy, and small or complex structures. Measure edit burden, rejection, downstream plan effects, and reviewer agreement rather than relying only on average overlap metrics.

product family · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model total annual and per-plan cost against hands-on and elapsed time after review, correction, failed transfers, rework, support, upgrades, downtime, and any effect on plan quality or throughput.

product family · checked 2026-09-03

Vendor time-saving results are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.

product family · checked 2026-09-03

Trend failures and edits by exact software version, model, anatomy, scanner, protocol, and site.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K201232
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-08-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
10Source classes checked
5Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials, current product-family materials, directly relevant clinical literature, reimbursement context, and exact-identifier recall candidates were reviewed. Pricing, final security architecture, contracted services, enabled modules or models, interoperability, and local acceptance remain organization-specific evidence. Automated exact-name discovery found 5 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, health technology guidance, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared release was found. Obtain a written quote separating license basis, sites or users, enabled modules or models, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

11 sources - 2 history items

Source ledger

  1. K201232 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning

    National Institute for Health and Care Excellence - Published 2023-09-27 - Accessed 2026-09-02

    Scope: limitations, training, pricing, evidenceSummary, economics, monitoring, implementationCapabilities

  8. Limbus Contour automatic contouring for radiation therapy

    Limbus AI, Inc. - Accessed 2026-09-03

    Scope: productFamily, integration, deployment, security, currentCommercialContext, implementationCapabilities

  9. Clinical evaluation of Limbus software for prostate and nodes radiotherapy contouring

    British Journal of Radiology - Published 2024-05-29 - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, economics, monitoring, implementationCapabilities

  10. Implementation of commercial deep-learning auto-segmentation in radiotherapy

    Life - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, economics, monitoring, implementationCapabilities

  11. Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas

    BMC Cancer - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring, implementationCapabilities

Research history

  1. K201232 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K240398

RayStation 2023B, RayPlan 2023B, RayStation 2024A, RayPlan 2024A, RayStation 2024A SP3, RayPlan 2024A SP3

RaySearch Laboratories AB (PUBL)

Authorized purpose: RayStation and RayPlan releases covered by K240398 are configurable radiotherapy and medical-oncology software that proposes or supports treatment plans from user inputs, with authorized users required to review and approve plans before treatment.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-04
FDA-cleared K242822

ART-Plan+ (v.3.0.0)

Therapanacea SAS

Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-02-25
FDA-cleared K242994

OncoStudio (OS-01)

OncoSoft. Co., Ltd.

Authorized purpose: OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-02-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history